Trial Profile

A phase 1b study of ORIC-944 in combination with NUBEQA (darolutamide) and ERLEADA (apalutamide) in patients with metastatic prostate cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ORIC-944 (Primary) ; Apalutamide; Darolutamide
Indications Prostate cancer
Focus Adverse reactions

Most Recent Events

28 May 2025 According to an ORIC Pharmaceuticals media release, company will host a conference call and webcast today at 4:30 p.m. ET to discuss the data.
28 May 2025 According to an ORIC Pharmaceuticals media release, company is looking forward to subsequent updates from the dose exploration and dose optimization portion of the Phase 1b trial over the next three quarters as we move towards initiating our first global registrational trial in 1H 2026.
28 May 2025 Results presented in the ORIC Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com